Skip Navigation

Annals of Oncology 2009 20(11):1755; doi:10.1093/annonc/mdp511
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   gefitinib for hormone-resistant and hormone receptor-negative advanced breast cancer
 
Preclinical studies have indicated a potential role for gefitinib in the treatment of breast cancer. In experiments with MCF7 cells resistant to tamoxifen and the antiestrogen fulvestrant, increased dependence on epidermal growth factor receptor (EGFR) signaling and sensitivity to gefitinib has been demonstrated. In a preclinical model, gefitinib has been shown to reverse tamoxifen resistance in . . . [Full Text of this Article]


   bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer
 

   prognostic significance of mid- and post-ABVD PET in Hodgkin's lymphoma
 

   imatinib plus sirolimus for advanced chordoma
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
M. D. Green, P. A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Basser, J. F. Forbes, and on behalf of the Australian New Zealand Breast Cancer Trials Group
Ann Oncol 2009 20: 1813-1817. [Abstract] [Full Text]  

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy
D. J. Sher, P. M. Mauch, A. Van Den Abbeele, A. S. LaCasce, J. Czerminski, and A. K. Ng
Ann Oncol 2009 20: 1848-1853. [Abstract] [Full Text]  

Response to imatinib plus sirolimus in advanced chordoma
S. Stacchiotti, A. Marrari, E. Tamborini, E. Palassini, E. Virdis, A. Messina, F. Crippa, C. Morosi, A. Gronchi, S. Pilotti, and P. G. Casali
Ann Oncol 2009 20: 1886-1894. [Abstract] [Full Text]